John W. Walsh Alpha-1 Home Infusion Act of 2022
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 31, 2022)
John W. Walsh Alpha-1 Home Infusion Act of 2022
This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
What just happenedApr 1, 2022
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 31, 2022
- Apr 1, 2022Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 31, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Mar 31, 2022IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Mar 31, 2022IntroReferralIntro-H
Introduced in House
- Mar 31, 2022IntroReferral1000
Introduced in House